… to find the needle faster. In-silico drug repurposing studies are a fast and efficient way to screen for new drug candidates to combat new or rare diseases. We also provide in-silico predictions of unexpected drug side effects before elaborated clinical trials for new drug discovery in the pharmaceutical and healthcare industries.
Even though our platforms are ready-to-use, we do not believe in one-fits-all solutions. Tailor-made software solutions help you optimize your R&D pipeline and redefine how you solve problems. Our developers are committed to eliminating bottlenecks and adapting our CatalophoreTM platform to your needs. Our AI-driven technologies learn and grow with your projects and are customizable to your goals.
Since the onset of the COVID-19 pandemic, we have been able to help shed more light on the nature of the SARS-CoV-2 virus through a series of studies.
Read more here.
In a recent structural bioinformatics approach, we gained new insights into the impact of amino acid exchanges on the affinity of the spike RBD for the human receptor hACE2.
Read more here: Structural bioinformatics analysis of SARS-CoV-2 variants reveals higher hACE2 receptor binding affinity for Omicron B.1.1.529 spike RBD compared to wild type reference
Durmaz, V., Köchl, K., Krassnigg, A. et al., Sci Rep 12, 14534 (2022).